Acquisitions (Details) (USD $)	3 Months Ended									3 Months Ended				0 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013	Mar. 31, 2014 R&D- and commercialization-based milestones [Member]	Mar. 31, 2014 R&D- and commercialization-based milestones [Member] Minimum [Member]	Mar. 31, 2014 R&D- and commercialization-based milestones [Member] Maximum [Member]	Mar. 31, 2014 revenue-based payments [Member] Discounted cash flow [Member]	Mar. 31, 2014 revenue-based payments [Member] Discounted cash flow [Member] Minimum [Member]	Mar. 31, 2014 revenue-based payments [Member] Discounted cash flow [Member] Maximum [Member]	Mar. 31, 2014 revenue-based payments [Member] Monte Carlo [Member]	Mar. 31, 2014 revenue-based payments [Member] Monte Carlo [Member] Minimum [Member]	Mar. 31, 2014 revenue-based payments [Member] Monte Carlo [Member] Maximum [Member]	Mar. 31, 2014 IoGyn [Member]	May 07, 2014 Subsequent Event [Member]
Business Acquisition [Line Items]
Accrued Contingent Consideration	$ (472,000,000)		$ (501,000,000)
Business Combination, Liabilities Arising from Contingencies, Amount Recognized	(3,000,000)	0
Adjustments to accrued contingent consideration	(2,000,000)
Benefit related to change in fair value of contingent liability	22,000,000
Contingent payment related to business combination	12,000,000
Maximum future contingent consideration for acquisitions	2,200,000,000
Business Combination, Contingent Consideration, Liability				(87,000,000)			(131,000,000)			(254,000,000)
Revenue Volatility - Contingent Consideration										13.00%
contingent consideration liability, projected year of payment					2014	2015		2014	2018		2014	2018
contingent consideration liability, probability of payment					85.00%	95.00%		0.00%	100.00%	19.00%
Risk-adjusted discount rate for contingent consideration					0.70%	1.40%		11.50%	15.00%
Minority interest owned of IoGyn	28.00%
Accounts and Notes Receivable, Net													8,000,000
Payments to Acquire Businesses, Net of Cash Acquired	$ 8,000,000	$ 0												$ 65,000,000
Remaining equity of IoGyn purchased														72.00%